[Comment] Stereotactic ablative radiotherapy for inoperable stage I NSCLC
02:35 EDT 23 Jun 2012 | The Lancet
Over the past 10 years, stereotactic ablative radiotherapy (SABR) has emerged as a viable treatment option for inoperable stage I non-small-cell lung cancer (NSCLC). In prospective and large retrospective studies in patients with considerable comorbi..
Original Article: [Comment] Stereotactic ablative radiotherapy for inoperable stage I NSCLC
More From BioPortfolio on "[Comment] Stereotactic ablative radiotherapy for inoperable stage I NSCLC"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
